New Q&A on the obligation to inform in case of interruption or discontinuation of supply
- Home
- regulatory updates
- New Q&A on the obligation to inform in case of interruption or discontinuation of supply
New Q&A on the obligation to inform in case of interruption or discontinuation of supply
Tuesday, 05 November 2024
Kirsten Van Garsse, Director AR Services and Manager IVD - RA and Anne Paulussen Senior Consultant IVD - RA
Share
\
\
X (Twitter) 
\
\
LinkedIn 
\
\
WhatsApp 
\
\
Copy link 
\
\
Mail
On October 30th, 2024, the Medical Device Coordination Group (MDCG) released a Q&A on the obligation to inform in case of interruption or discontinuation of supply. This document provides a Q&A related to Article 10a as introduced by Regulation (EU) 2024/1860 amending Regulations (EU) 2017/745 and (EU) 2017/746.
Some key takeaways from the Q&A
With the exception of custom-made devices, Article 10a will apply as of 10 January 2025 to all models or types of devices including legacy devices, and the legal manufacturer cannot delegate its legal responsibility for this task, however it can engage the assistance of its authorised representative, other economic operators or a third party, in the practical implementation of the required operational tasks. The notified economic operators are responsible to cascade the information as provided by the legal manufacturer to downstream supply chain.
The Q&A also includes an example of the onward information sharing in the context of a supply interruption where the manufacturer does not directly supply to the health institution. In addition, information is provided on the timelines on when the manufacturer should inform under Article 10a.
Further, the Q&A provides clearer definitions and examples for “exceptional circumstances”, “anticipation of an ‘interruption or discontinuation’ of the supply of a device” and “interruption or discontinuation that may result in serious harm or a risk of serious harm to patients or public health”. The document also provides information on which indicators the manufacturer can take into account when performing its assessment.
In the future, the manufacturer must provide information as required in the “ Manufacturer Information Form”, which is currently not available yet. It should be noted that Member States may provide additional information on how to submit the information in the form, on the websites of the relevant competent authority.
Lastly, the Q&A provides clarity that Article 10a applies to manufacturers of individual CE-marked devices within a system or procedure pack. These manufacturers are responsible for informing the relevant parties, as outlined in Article 10a (1) of the MDR/IVDR, including the competent authority and the system or procedure pack producer, about any interruption or discontinuation of their devices.
What does it mean to you?
The Q&A document assists IVD and medical device manufacturers in addressing questions related to the new supply interruption notification requirements in Regulation (EU) 2024/1860. Developed with the amendment’s objectives in mind, it clarifies manufacturers’ information-sharing obligations introduced in Article 10a.
Need regulatory support?
Trust our expertise to guide you through the regulatory process and achieve compliance
with ease.
Discover how we can help.
Discover more expert content
Previous
Regulatory Affairs
14 Oct 2024
MDCG 2024-12 released
It includes detailed sections on corrections, root cause analysis, corrective and preventive...
Regulatory Affairs
9 Jul 2024
MDCG: First Revision on the Guidance on Standardisation for Medical Devices
MDCG 2021-05 Revision 1: Guidance on standardization for medical devices The scope of this...
Regulatory Affairs
14 Oct 2024
MDCG 2024-11 released
Regulatory Affairs
27 Jun 2024
MDCG 2024-10: Clinical Evaluation Guidelines for Orphan Medical Devices
MDCG 2024-10 Clinical evaluation of orphan medical devicesThis document provides guidance to...
Regulatory Affairs
29 Oct 2024
First Revision of MDCG 2021-25 Released
Application of MDR requirements to “legacy devices” and to devices placed on the market prior to...
Regulatory Affairs
14 Oct 2024
MDCG 2024-12 released
It includes detailed sections on corrections, root cause analysis, corrective and preventive...
Regulatory Affairs
9 Jul 2024
MDCG: First Revision on the Guidance on Standardisation for Medical Devices
MDCG 2021-05 Revision 1: Guidance on standardization for medical devices The scope of this...
Regulatory Affairs
14 Oct 2024
MDCG 2024-11 released
Regulatory Affairs
27 Jun 2024
MDCG 2024-10: Clinical Evaluation Guidelines for Orphan Medical Devices
MDCG 2024-10 Clinical evaluation of orphan medical devicesThis document provides guidance to...
Regulatory Affairs
29 Oct 2024
First Revision of MDCG 2021-25 Released
Application of MDR requirements to “legacy devices” and to devices placed on the market prior to...
Regulatory Affairs
14 Oct 2024
MDCG 2024-12 released
It includes detailed sections on corrections, root cause analysis, corrective and preventive...
Regulatory Affairs
9 Jul 2024
MDCG: First Revision on the Guidance on Standardisation for Medical Devices
MDCG 2021-05 Revision 1: Guidance on standardization for medical devices The scope of this...
Next
- 1
- 2
- 3
Stay ahead in life sciences
Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.
Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.
Twitter Widget Iframe